NASDAQ:OBSV - ObsEva Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $14.33
Forecasted Upside: 539.88 %
Number of Analysts: 3
Breakdown:
0 Sell Ratings
0 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$2.24 As of 11/26/2021 01:00 AM ET

+0.30 (1.20%)

1 month | 3 months | 12 months

Get New ObsEva Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for OBSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBSV

^$14.33

▲ +539.88% Upside Potential

This price target is based on 3 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $14.33, with a high forecast of $21.00 and a low forecast of $5.00. The average price target represents a 539.88% upside from the last price of $2.24.

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in ObsEva. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/5/2020

0 strong buy ratings
4 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

9/3/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/2/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/2/2021

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

5/31/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

8/29/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

10/28/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/27/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/17/2021	Wedbush	Reiterated Rating	Buy	$21.00	High
9/15/2021	HC Wainwright	Reiterated Rating	Buy	$17.00	Medium
8/9/2021	HC Wainwright	Reiterated Rating	Buy	$17.00	Low
7/28/2021	Wedbush	Reiterated Rating	Buy	$21.00	Low
7/2/2021	Wedbush	Reiterated Rating	Buy	$24.00	N/A
1/12/2021	Wedbush	Reiterated Rating	Buy	$28.00	Low
1/12/2021	SVB Leerink	Boost Price Target	Outperform	$4.00 ➝ $5.00	Low
1/4/2021	HC Wainwright	Lower Price Target	Buy	$23.00 ➝ $17.00	N/A
11/9/2020	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Medium
10/5/2020	HC Wainwright	Lower Price Target	Buy	$36.00 ➝ $23.00	High
8/14/2020	Wedbush	Reiterated Rating	Buy	$30.00	High
7/7/2020	SVB Leerink	Lower Price Target	Outperform	$7.00 ➝ $5.00	High
7/7/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$18.00 ➝ $5.00	High
7/6/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$5.00 ➝ $4.00	High
7/1/2020	HC Wainwright	Reiterated Rating	Buy	$36.00	Low
7/1/2020	Wedbush	Reiterated Rating	Buy	$30.00	Low
6/5/2020	HC Wainwright	Reiterated Rating	Buy	$36.00	High
5/5/2020	Wedbush	Reiterated Rating	Buy	$30.00	High
3/23/2020	Wedbush	Reiterated Rating	Buy	$40.00 ➝ $34.00	Medium
3/23/2020	HC Wainwright	Lower Price Target	Buy	$40.00 ➝ $36.00	Low
3/5/2020	Wedbush	Boost Price Target	Outperform	$36.00 ➝ $40.00	High
1/21/2020	Wedbush	Reiterated Rating	Buy	$36.00	High
1/21/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	High
12/19/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $40.00	High
12/10/2019	Royal Bank of Canada	Boost Price Target	Outperform	$18.00 ➝ $19.00	High
12/2/2019	HC Wainwright	Reiterated Rating	Buy	$44.00 ➝ $36.00	Low
11/8/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$16.00 ➝ $4.00	High
10/31/2019	Wedbush	Reiterated Rating	Buy	$38.00	Medium
10/11/2019	Wedbush	Set Price Target	Buy	$38.00	Low
9/4/2019	HC Wainwright	Reiterated Rating	Buy	$44.00	Low
8/11/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low
7/29/2019	Credit Suisse Group	Lower Price Target	Outperform	$24.00 ➝ $16.00	Medium
7/18/2019	Wedbush	Reiterated Rating	Outperform	$38.00	High
7/8/2019	Wedbush	Set Price Target	Buy	$38.00	Low
6/19/2019	Wedbush	Reiterated Rating	Buy	$38.00	Medium
6/5/2019	HC Wainwright	Set Price Target	Buy	$44.00	Medium
5/28/2019	HC Wainwright	Reiterated Rating	Buy	$44.00	Low
5/10/2019	Wedbush	Set Price Target	Buy	$38.00	Medium
5/6/2019	HC Wainwright	Reiterated Rating	Buy		Low
4/29/2019	HC Wainwright	Reiterated Rating	Buy		Low
3/7/2019	HC Wainwright	Set Price Target	Buy	$44.00	Low
1/25/2019	Wedbush	Set Price Target	Buy	$34.00	High
1/23/2019	HC Wainwright	Set Price Target	Buy	$44.00	Low
1/15/2019	Wedbush	Set Price Target	Buy	$34.00	High
1/4/2019	HC Wainwright	Set Price Target	Buy	$44.00	Low
12/11/2018	Wedbush	Reiterated Rating	Buy	$34.00	Low
12/10/2018	HC Wainwright	Reiterated Rating	Buy	$44.00	Low
10/15/2018	HC Wainwright	Set Price Target	Buy	$44.00	Low
10/3/2018	Wedbush	Set Price Target	Buy	$34.00	High
9/13/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$29.00	Low
8/29/2018	HC Wainwright	Set Price Target	Buy	$44.00	High
8/15/2018	SVB Leerink	Initiated Coverage	Outperform	$25.00	Low
8/8/2018	HC Wainwright	Set Price Target	Buy	$44.00	High
8/6/2018	Wedbush	Initiated Coverage	Outperform	$34.00	High
7/25/2018	HC Wainwright	Set Price Target	Buy	$30.00	Low
7/19/2018	Credit Suisse Group	Initiated Coverage	Outperform	$24.00	Low
7/16/2018	HC Wainwright	Set Price Target	Buy	$30.00	High
6/18/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$23.00 ➝ $31.00	High
6/12/2018	BMO Capital Markets	Initiated Coverage	Outperform	$23.00	High
6/11/2018	HC Wainwright	Set Price Target	Buy	$28.00	Low
5/29/2018	HC Wainwright	Reiterated Rating	Buy	$28.00	Medium
3/9/2018	HC Wainwright	Reiterated Rating	Buy	$27.00	Low
2/27/2018	BMO Capital Markets	Reiterated Rating	Buy	$24.00	High
2/27/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00	High
2/27/2018	Credit Suisse Group	Reiterated Rating	Outperform ➝ Buy	$16.00 ➝ $18.00	Low
2/5/2018	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
1/4/2018	HC Wainwright	Set Price Target	Buy	$25.00	Low
12/14/2017	HC Wainwright	Set Price Target	Buy	$25.00	Low
12/4/2017	BMO Capital Markets	Initiated Coverage	Outperform	$20.00	Low
11/29/2017	HC Wainwright	Set Price Target	Buy	$25.00	Low
11/8/2017	HC Wainwright	Reiterated Rating	Buy	$25.00	N/A
11/2/2017	Royal Bank of Canada	Reiterated Rating	Buy	$22.00	N/A
10/30/2017	HC Wainwright	Set Price Target	Buy	$25.00	N/A
10/11/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $25.00	N/A
10/9/2017	Credit Suisse Group	Initiated Coverage	Outperform	$27.00 ➝ $16.00	N/A
10/4/2017	HC Wainwright	Reiterated Rating	Buy	$27.00	High
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$22.00	Low
9/8/2017	HC Wainwright	Reiterated Rating	Buy	$27.00	Low
8/16/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$18.00	High
8/16/2017	HC Wainwright	Set Price Target	Buy	$27.00	Low
6/29/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$27.00	High
4/18/2017	Credit Suisse Group	Reiterated Rating	Outperform	$27.00	Low
2/21/2017	SVB Leerink	Initiated Coverage	Outperform	$21.00	N/A
2/21/2017	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$27.00	N/A
2/21/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$21.00	N/A

(Data available from 11/27/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/1/2021

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/31/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/30/2021

1 very positive mentions
7 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

7/30/2021

2 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/29/2021

1 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/28/2021

0 very positive mentions
9 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

10/28/2021

3 very positive mentions
13 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/27/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Today's Range

Now: $2.24

$2.17

$2.25

50 Day Range

MA: $2.75

$2.19

$3.34

52 Week Range

Now: $2.24

$1.93

$5.55

Volume

386,807 shs

Average Volume

2,567,646 shs

Market Capitalization

$174.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?: The following Wall Street sell-side analysts have issued reports on ObsEva in the last year: HC Wainwright, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for OBSV.
What is the current price target for ObsEva?: 3 Wall Street analysts have set twelve-month price targets for ObsEva in the last year. Their average twelve-month price target is $14.33, suggesting a possible upside of 539.9%. Wedbush has the highest price target set, predicting OBSV will reach $21.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $5.00 for ObsEva in the next year.
View the latest price targets for OBSV.
What is the current consensus analyst rating for ObsEva?: ObsEva currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OBSV will outperform the market and that investors should add to their positions of ObsEva.
View the latest ratings for OBSV.
What other companies compete with ObsEva?: Other companies that are similar to ObsEva include Chinook Therapeutics, Kronos Bio, Affimed, Cara Therapeutics, Atea Pharmaceuticals, Emisphere Technologies, Kezar Life Sciences, Prelude Therapeutics, Silence Therapeutics, Oramed Pharmaceuticals, Zogenix, OrganiGram, SIGA Technologies, BioXcel Therapeutics and Vera Therapeutics.
How do I contact ObsEva's investor relations team?: ObsEva's physical mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company's listed phone number is (122) 552-3840 and its investor relations email address is [email protected] The official website for ObsEva is www.obseva.com.

NASDAQ:OBSV - ObsEva Stock Price Target and Predictions

Analyst Price Target for OBSV

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.39 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

What is the current price target for ObsEva?

What is the current consensus analyst rating for ObsEva?

What other companies compete with ObsEva?

How do I contact ObsEva's investor relations team?